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A total of 1,537 clinical isolates of Haemophilus influenzae were recovered in 30 U.S. medical center labora-
tories between 1 November 1994 and 30 April 1995 and were characterized in a central laboratory with respect
to serotype and b-lactamase production and the in vitro activities of 15 oral antimicrobial agents. Overall,
36.4% of the isolates were found to produce b-lactamase. The rank order of activity of six cephalosporins on
the basis of MICs was cefixime > cefpodoxime > cefuroxime > loracarbef > cefaclor > cefprozil. On the basis
of current National Committee for Clinical Laboratory Standards (NCCLS) breakpoints, the overall percent-
ages of isolates found to be resistant or intermediate to these agents were as follows: 0.1, 0.3, 6.4, 16.3, 18.3, and
29.8, respectively (National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial
susceptibility tests for bacteria that grow aerobically, 4th ed. M7-A4, 1995). Azithromycin was, on a weight
basis, the most potent of the macrolides tested in this study, followed by erythromycin and then clarithromycin.
Azithromycin was typically fourfold more active than erythromycin, which was, in turn, slightly more active
than clarithromycin. However, when compared on the basis of the frequency of resistance determined by using
current NCCLS breakpoints, there was essentially no difference between azithromycin and clarithromycin, i.e.,
0.5 and 1.9%, respectively (P 5 0.086). Interpretive breakpoints for erythromycin MIC tests versus H.
influenzae have not been developed. Resistance to other non-b-lactam agents was variable, as follows: tri-
methoprim-sulfamethoxazole, 9.0%; chloramphenicol, 0.2%; tetracycline, 1.3%; and rifampin, 0.3%. Two con-
spicuous findings in this study were the identification of 39 strains of H. influenzae that were b-lactamase
negative but ampicillin intermediate or resistant (BLNAR) and, even more surprisingly, 17 b-lactamase-
positive isolates that were resistant to amoxicillin-clavulanate (BLPACR). Strains of H. influenzae in the first
group have heretofore been very uncommon; organisms in the second group have not previously been described
in the literature. The percentages of all study isolates comprised of BLNAR and BLPACR organisms were 2.5
and 1.1, respectively. Overall resistance to ampicillin was thus 38.9%, and that to amoxicillin-clavulanate was
4.5%.
Haemophilus influenzae is recognized as a frequent cause of
a variety of infections among outpatients, including acute otitis
media, sinusitis, acute purulent exacerbation of chronic bron-
chitis, and pneumonia. These infections are usually caused by
non-type b strains of H. influenzae. Life-threatening invasive
infections more commonly caused by encapsulated type b
strains have largely disappeared, at least in circumstances and
areas in which the protein-conjugated type b capsular polysac-
charide vaccine has been used (3). Since localized infections
such as those caused by non-type b H. influenzae isolates are
often treated empirically, a knowledge of antibiotic resistance
determined on the basis of systematic surveillance studies is
essential.
Since the first description of b-lactamase-mediated ampicil-
lin resistance in H. influenzae in the United States in 1974 (15,
27), this problem has become increasingly more prevalent (1,
6–9, 11, 12, 23). The last systematic U.S. national surveillance
study conducted in 1993 revealed a prevalence of 33% b-lac-
tamase production among non-type b H. influenzae isolates
(23). In addition, resistance to oral cephalosporins, macrolides,
and other orally administered agents such as trimethoprim-
sulfamethoxazole (TMP-SMX), chloramphenicol, and tetracy-
cline has been described (1, 8, 9, 12). In 1980, the problem of
antibiotic resistance among H. influenzae isolates was compli-
cated further by the description of b-lactamase-negative strains
which were resistant to ampicillin by some other mechanism (2,
17), perhaps elaboration of altered penicillin-binding proteins
(5, 16, 19, 22). These strains, referred to as b-lactamase neg-
ative but ampicillin intermediate or resistant (BLNAR) have
fortunately remained uncommon, at least in the United States
and Canada (1, 8, 12, 25, 26).
The intent of the current investigation was to define the
contemporary levels of resistance to 15 oral antimicrobial
agents for a large number of isolates of H. influenzae obtained
from patients with a variety of community-acquired infections
in 30 U.S. medical centers. This may be considered a point
prevalence study since all isolates were collected during the
* Corresponding author. Mailing address: Clinical Microbiology
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relatively narrow 6-month time frame of 1 November 1994
through 30 April 1995. All analyses were performed in a cen-
tral laboratory.
MATERIALS AND METHODS
Bacterial isolates and identification. Between 1 November 1994 and 30 April
1995, a total of 1,537 unique patient isolates of H. influenzae were obtained from
various specimen sources from outpatients in 30 different U.S. medical centers.
Isolates were collected consecutively and were transported to the University of
Massachusetts Medical Center on rayon swabs immersed in 12 ml of Aimes
semisolid transport medium containing charcoal. Stock cultures were prepared
by using an absorbent bead system (ProLab Diagnostics, Austin, Tex.), and
organisms were stored at 2708C until further use. All organisms were subcul-
tured twice on chocolate agar prior to further characterization. Isolates were
confirmed as H. influenzae by using conventional criteria (4), and serotyping was
performed by a slide agglutination procedure with type b antiserum (Murex
Diagnostics, Inc., Atlanta, Ga.).
Susceptibility studies. MICs were determined as described by the National
Committee for Clinical Laboratory Standard (NCCLS) (21) by a broth microdi-
lution procedure (100-ml total volume per well; final inoculum concentration, ca.
5 3 105 CFU/ml), with the trays incubated at 358C in ambient air for 22 to 24 h
prior to determining the results. Haemophilus Test Medium (HTM) broth was
used for MIC determinations withH. influenzae (13). Fifteen antibiotics obtained
from their respective manufacturers as laboratory-grade powders were each
tested at 12 different concentrations in an attempt to limit the number of off-scale
results. The antibiotics included ampicillin, amoxicillin-clavulanate (A-C; 2:1),
cefaclor, loracarbef, cefprozil, cefuroxime, cefixime, cefpodoxime, erythromycin,
azithromycin, clarithromycin, TMP-SMX (1:19), chloramphenicol, tetracycline,
and rifampin. H. influenzae ATCC 49247, ATCC 49766, and ATCC 10211 were
used as controls. b-Lactamase production was assessed for all isolates by the
nitrocefin disk assay (Cefinase; Becton-Dickinson Microbiology Systems, Cock-
eysville, Md.) (20).
RESULTS
A total of 1,537 isolates of Haemophilus influenzae were
characterized in this investigation (Table 1). A range of from
13 to 76 isolates were contributed by each of the 30 participat-
ing medical center laboratories (Table 1). Among these, 560
(36.4%) produced b-lactamase. The proportion of isolates
found to produce b-lactamase in individual centers varied from
17.0 to 68.3%. Only 17 isolates (1.2%) among a total of 1,469
strains characterized produced type b capsular antigen.
Males yielded 55.4% of isolates; there was no significant
difference in b-lactamase production between isolates from
males and females (Table 2). Table 2 also depicts the distri-
bution of test strains by patient age and specimen type. Isolates
were most commonly obtained in specimens from the lower
respiratory tract. b-Lactamase production was most often
found among organisms recovered from middle ear fluid, sinus
aspirates, and conjunctival swab specimens, specimens usually
representative of Haemophilus infections in children. Consis-
tent with this observation was the finding that isolates from
children ages 0 to 5 years had the highest frequency of b-lac-
tamase production (i.e., 45.8%). Among middle ear fluid, sinus
aspirate, and conjunctival swab specimens, 72.5% were ob-
tained from patients 0 to 5 years old. By contrast, sputum
specimens yielded isolates which were b-lactamase positive
31.5% of the time; 78.1% of isolates in sputum specimens came
from individuals $21 years old. One final observation regard-
ing the source of isolates deserves mention. Among a total of
33 isolates obtained on blood culture, 21 (63.6%) were recov-
ered from adults $21 years of age, 14 (42.4%) were from
patients $50 years old, and 8 (24.2%) were obtained from
children #5 years old.
Results of MIC determinations with 15 antimicrobial agents
are presented in Table 3. The rank order of activity of the six
cephalosporins examined in this study was cefixime . cefpo-
TABLE 1. Prevalence of b-lactamase production among clinical isolates of H. influenzae recovered from outpatients at 30 different U.S.
medical centers between 1 November 1994 and 30 April 1995
Medical center City Total no.of isolates
% of isolates
b-lactamase positive
Children’s Hospital Boston, Mass. 42 31.0
University of Massachusetts Medical Center Worcester, Mass. 76 23.7
Hartford Hospital Hartford, Conn. 68 38.2
SUNY Medical Center Syracuse, N.Y. 39 33.3
Strong Memorial Hospital Rochester, N.Y. 58 27.6
Columbia-Presbyterian Hospital New York, N.Y. 61 29.5
Temple University Medical Center Philadelphia, Pa. 47 17.0
Geisinger Medical Center Danville, Pa. 56 35.7
National Children’s Hospital Washington, D.C. 13 23.1
University of North Carolina Medical Center Chapel Hill, N.C. 61 45.9
DeKalb General Hospital Decateur, Ga. 58 34.5
Mt. Sinai Hospital Miami, Fla. 51 29.4
University of South Alabama Medical Center Mobile, Ala. 61 42.6
Cleveland Clinic Cleveland, Ohio 57 28.1
Henry Ford Hospital Detroit, Mich. 63 68.3
Methodist Hospital Indianapolis, Ind. 64 37.5
Rush Presbyterian Medical Center Chicago, Ill. 44 45.5
Evanston Hospital Evanston, Ill. 45 44.4
Children’s Hospital Milwaukee, Wis. 50 26.0
Mayo Clinic Rochester, Minn. 45 46.7
Jewish Hospital St. Louis, Mo. 67 29.9
University of Texas Southwestern Medical Center Dallas, Tex. 38 36.8
Texas Children’s Hospital Houston, Tex. 28 50.0
Denver General Hospital Denver, Colo. 32 31.3
Primary Children’s Hospital Salt Lake City, Utah 61 54.1
Good Samaritan Hospital Phoenix, Ariz. 64 32.8
Cedar’s Sinai Hospital Los Angeles, Calif. 16 56.3
Stanford University Medical Center Palo Alto, Calif. 54 18.5
Kaiser Medical Center Portland, Oreg. 62 35.5
Children’s Hospital Seattle, Wash. 55 45.5
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doxime . cefuroxime . loracarbef $ cefaclor . cefprozil. On
the basis of current NCCLS breakpoints, the percentages of
isolates found to be resistant to these agents were 0.1, 0.3, 1.5,
8.1, 8.0, and 14.6, respectively (21). The percentages of strains
noted to be intermediate to cefuroxime, loracarbef, cefaclor,
and cefprozil were 4.9, 8.2, 10.3, and 15.2, respectively. Inter-
pretive criteria for an intermediate category have not been
defined for cefixime or cefpodoxime (21). On the basis of a
comparison of the MICs at which 50% of isolates are inhibited
(MIC50s), MIC90s, and geometric mean MICs plus resistance
rates, it appeared that the activities of loracarbef, cefaclor, and
cefprozil against b-lactamase-positive strains were slightly di-
minished compared with those against b-lactamase-negative
strains. b-Lactamase production did not influence the activity
of cefpodoxime, cefixime, or cefuroxime.
The rank order of activity on a weight basis with the mac-
rolide agents was azithromycin . erythromycin $ clarithromy-
cin. MIC interpretive breakpoints have been defined by
NCCLS only for azithromycin and clarithromycin (21). By us-
ing these breakpoints, there was only a small difference be-
tween the percentages of strains that were resistant to these
two agents, i.e., 0.5 and 1.9, respectively. Overall, however,
27.1% of isolates were noted to be intermediate to clarithro-
mycin. Breakpoints for an azithromycin intermediate category
have not been defined.
Again, on the basis of the breakpoints defined by NCCLS
(21), resistance was more common to TMP-SMX (9.0%) than
to chloramphenicol (0.2%), tetracycline (1.3%), or rifampin
(0.3%). Eighty-eight (64.2%) of the TMP-SMX-resistant
strains produced b-lactamase. With the exception of one TMP-
SMX-resistant strain which was found to be resistant to both
tetracycline and rifampin, TMP-SMX resistance usually oc-
curred in the absence of resistance to other non-b-lactam
agents. Of note, all three chloramphenicol-resistant isolates
produced b-lactamase and were also resistant to tetracycline.
A total of 39 b-lactamase-negative strains (4.0% of all b-lac-
tamase-negative isolates) were found to be resistant (MICs,$4
mg/ml; n 5 13) or intermediate (MICs, 2 mg/ml; n 5 26) to
ampicillin and thus were categorized as BLNAR. Ampicillin
MIC determinations were repeated with these 39 strains in a
second lot of HTM broth and never varied by more than 61
twofold concentration increment (data not shown). Twenty-
eight of these 39 strains were resistant to A-C (MICs, $8
mg/ml); the A-C MICs for the remaining 11 strains categorized
as BLNAR were 4.0 mg/ml. By comparison, the modal ampi-
cillin and A-C MICs for b-lactamase-negative, ampicillin-sus-
ceptible strains (i.e., strains for which ampicillin MICs were
#1.0 mg/ml) were 0.25 to 0.5 and 1.0 mg/ml, respectively.
Further evidence that these 39 apparent BLNAR strains
were indeed distinct from typical ampicillin-susceptible, b-lac-
tamase-negative organisms could be found in comparisons of
the activities of the cephalosporins against these two groups of
H. influenzae. The modal MICs of cefaclor, loracarbef, cefpro-
zil, cefuroxime, cefixime, and cefpodoxime for BLNAR strains
were 16 to 32, 16, 32, 4 to 8, 0.06, and 0.25 to 0.5 mg/ml,
respectively. In all cases, these values were much higher than
the modal MICs obtained with the same agents versus ampi-
TABLE 2. Source of clinical isolates of H. influenzae by patient






% of isolates b-
lactamase positive P value
a
Gender
Male 847 (55.4) 35.7
Female 683 (44.6) 37.2 NS
Age group (yr)
0–5 428 (28.0) 45.8
6–10 74 (4.8) 32.4 NS
11–20 98 (6.4) 34.7 NS
21–50 357 (23.4) 32.5 #0.001
$51 570 (37.3) 32.1 #0.001
Specimen type
Middle ear fluid 78 (5.1) 46.1
Sinus aspirate 72 (4.7) 56.9 NS
Conjunctival swab 232 (15.2) 51.7 NS
Lower respiratory tract 1064 (69.5) 31.5 0.008
Blood 34 (2.2) 26.5 NS
Cerebrospinal fluid 3 (0.2) 0.0 NS
Other 47 (3.1) 31.9 NS
a Chi-square analysis; in all cases, comparisons were made to the first entry in
a category. NS, not significant.
TABLE 3. MICs of 15 antimicrobial agents for 1,537 recent clinical isolates of H. influenzae
Antimicrobial agent
MIC (mg/ml)
b-Lactamase-negative isolates (n 5 977) b-Lactamase-positive isolates (n 5 560)
50% 90% Geometricmean Range 50% 90%
Geometric
mean Range
Ampicillin 0.25 1 0.38 #0.06–16 64 $256 62.3 2–$256
A-C 1 2 1.1 0.06–$32 1 4 1.5 0.25–16
Cefaclor 4 16 4.6 0.25–$256 4 32 6.6 0.25–128
Loracarbef 2 16 3.2 0.12–$128 4 64 5.7 0.25–$256
Cefprozil 8 16 6.5 0.25–128 8 64 12.0 0.5–$256
Cefuroxime 1 4 1.4 0.03–$32 1 4 1.3 0.06–$32
Cefixime 0.03 0.06 0.04 #0.004–$8 0.03 0.06 0.04 #0.004–$8
Cefpodoxime 0.12 0.25 0.1 #0.004–$4 0.06 0.12 0.09 #0.004–$4
Erythromycin 8 8 6.4 0.12–$64 8 8 6.4 0.25–$64
Azithromycin 2 2 1.7 0.06–$64 2 2 1.6 #0.015–$32
Clarithromycin 8 16 9.0 #0.06–$256 8 16 9.6 0.12–$128
TMP-SMX ,0.06 0.25 0.12 #0.06–32 #0.06 8 0.18 #0.06–32
Chloramphenicol 0.5 1 0.54 0.12–4 0.5 1 0.56 #0.06–16
Tetracycline 1 1 0.82 0.12–128 1 1 0.87 0.12–128
Rifampin 0.25 0.25 0.20 #0.03–$64 0.25 0.25 0.20 #0.03–16
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cillin-susceptible isolates, i.e., 4, 2 to 4, 4, 1.0, 0.03, and 0.06 to
0.12 mg/ml, respectively. If the 39 BLNAR strains were added
to the b-lactamase-positive isolates, the overall frequency of
ampicillin resistance was 38.9%.
A striking finding of this study was the identification of 17
b-lactamase-positive strains of H. influenzae (3.0% of all b-lac-
tamase-positive isolates) that were resistant to A-C (BLPACR).
Upon initial testing, A-C MICs for 12 of these strains were 8
mg/ml, and A-C MICs were 16 mg/ml for 5 strains. The A-C
MICs for these 17 strains were corroborated by repeat microdi-
lution testing in a second lot of HTM broth and in Mueller-
Hinton broth containing 3% lysed horse blood plus 15 mg of
NAD per ml. In addition, broth microdilution determinations
of A-C MICs were accomplished with these strains by using
commercially prepared panels containing dehydrated antibi-
otic (Just-One) reconstituted with a third lot of HTM broth.
Finally, A-C MICs were determined independently in a second
laboratory, the University of Texas Health Science Center at
San Antonio (11a), by the microdilution method in HTM
broth. The results of this extensive secondary testing were
judged to corroborate the initial MIC determinations (data not
shown).
For all 17 BLPACR strains, ampicillin MICs were $128
mg/ml. By contrast, the modal ampicillin MIC for b-lactamase-
positive strains that were susceptible to A-C (MICs,#4 mg/ml)
was 32 mg/ml. The modal MICs of cefaclor, loracarbef, cefpro-
zil, cefuroxime, and cefpodoxime (i.e., 16, 16, 32, 4, and 0.25
mg/ml, respectively) were consistently higher for b-lactamase-
positive, A-C-resistant strains than the modal MICs of the
same agents for b-lactamase-positive, A-C-susceptible isolates
(i.e., 4, 4, 8, 1, and 0.06 mg/ml, respectively). The 17 BLPACR
strains when added to the BLNAR strains that were also re-
sistant to A-C, yielding an overall prevalence of A-C resistance
of 4.5%.
DISCUSSION
The first recognition of b-lactamase-mediated ampicillin re-
sistance with H. influenzae occurred in 1974 (15, 27). It is now
understood that this organism may produce either of two
b-lactamases, TEM-1 or ROB-1 (14, 18, 24). One study re-
vealed that ca. 93% of b-lactamase-producing strains produced
the TEM-1 enzyme, and the remainder produced the ROB-1
enzyme (26). Eight large systematic national surveillance stud-
ies of the antibiotic resistance of H. influenzae isolates were
conducted in North America between 1982 and 1993; five in
the United States (1, 8, 9, 12, 23) and three in Canada (25, 26,
28). When restricted to non-type b strains of H. influenzae,
increases in b-lactamase-mediated ampicillin resistance of ca.
1 to 3% per year have occurred, reaching a level of 33% in
1993. The results of the current investigation suggest that the
prevalence of b-lactamase-mediated ampicillin resistance
among non-type b strains continues to grow and now exists at
a level of 36.4% overall in the United States. The issue of
antibiotic resistance of H. influenzae strains is appropriately
restricted to non-type b strains, since infections most com-
monly caused by encapsulated type b isolates (i.e., meningitis,
epiglottitis, facial cellulitis, and bacteremia) occur very infre-
quently today in developed countries such as the United States
because of the use of protein-conjugated capsular antigen vac-
cines (3).
Six cephalosporins were examined in this study. They could
be categorized into three groups on the basis of their activities
against H. influenzae. Loracarbef, cefaclor, and cefprozil had
MIC90s of 16 to 64 mg/ml, the combined percentages of strains
intermediate and resistant to these drugs were 16.3 to 29.8, and
the activities of the drugs appeared to be diminished by b-lac-
tamase production. The MIC90 of cefuroxime was 4 mg/ml;
1.5% of strains were resistant and 4.9% were intermediate to
cefuroxime, and the MIC50s, MIC90s, and geometric mean
MICs were essentially the same with b-lactamase-positive and
-negative strains. Cefixime and cefpodoxime were the most
active cephalosporins, with MIC90s of 0.06 to 0.25 mg/ml, the
frequencies of resistance to these drugs was 0.1 to 0.3%, and
no b-lactamase effect was detected.
This study revealed differences in the activities of three mac-
rolide agents against H. influenzae when they were assessed on
the basis of MICs. Azithromycin was consistently fourfold
more active than erythromycin, which in turn was slightly more
active than clarithromycin. These relationships were clear from
comparisons of MIC50s, MIC90s, and geometric mean MICs,
strain-by-strain comparisons of MICs, or comparisons of the
modal MICs derived from the unimodal MIC distributions
obtained with all three of the macrolides versus the collection
of isolates examined in this study. On the basis of NCCLS-
defined MIC breakpoints (21), 0.5% of strains would have
been judged to be resistant to azithromycin and 1.9% would
have been judged to be resistant to clarithromycin. No inter-
mediate category has been defined for azithromycin; for cla-
rithromycin, 27.1% of strains overall were classified as inter-
mediate (MICs, 16 mg/ml). No interpretive breakpoints have
been established for erythromycin (21). The question is
whether these differences in in vitro macrolide activity trans-
late into differences in efficacy in treating H. influenzae infec-
tions. This question is germane insofar as the MICs deter-
mined with clarithromycin alone, as was the case in this study,
may underestimate the activity of this agent in vivo, since the
additive or synergistic effect of the 14-OH metabolite of clar-
ithromycin, which occurs as a result of hepatic metabolism, is
not taken into consideration (10). This question can only be
answered by controlled clinical trials that directly compare
these agents.
The overall frequencies of resistance to other non-b-lactam
agents were as follows: TMP-SMX, 9.0%; chloramphenicol,
0.2%; tetracycline, 1.3%; and rifampin, 0.3%. These levels of
resistance are similar to those reported in a large surveillance
study conducted in the United States in 1992 and 1993 and
suggest that the frequencies of resistance to these agents are
not changing (1).
Of particular concern in this study was the recovery of 39
apparent BLNAR strains of H. influenzae (4.0% of b-lacta-
mase-negative isolates and 2.5% of all isolates). These were
strains for which ampicillin MICs were 2 mg/ml (i.e., interme-
diate) or$4 mg/ml (resistant). The actual distribution of MICs
for isolates in this group was 2 mg/ml (n 5 25), 4 mg/ml (n 5
9), 8 mg/ml (n5 1), and 16 mg/ml (n5 3). Heretofore, BLNAR
strains have not been recovered frequently in North America,
with frequencies of #0.1% reported in several recent national
surveillance studies (1, 8, 12, 25, 26). Because of the obvious
importance of our observations, determinations of the ampi-
cillin MICs for these strains were repeated with a second lot of
HTM broth. The b-lactamase assay was also repeated. The
results of this secondary testing corroborated the initial results.
It appears that BLNAR strains of non-type b H. influenzae are
now present in significant numbers in the United States. No
geographic or institutional clustering of these strains was rec-
ognized.
Examination of an ampicillin MIC frequency distribution
plot derived from the data generated with b-lactamase-nega-
tive strains in this study revealed a unimodal population with a
conspicuous modal MIC of 0.25 to 0.5 mg/ml. The MICs for the
39 BLNAR isolates were clustered at the higher end of this
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distribution. The question that arises is how different are the
BLNAR strains from typical b-lactamase-negative, ampicillin-
susceptible isolates? To answer this question, the MICs of six
cephalosporins for the BLNAR strains were compared with
those obtained for b-lactamase-negative, ampicillin-suscepti-
ble strains. In all cases, the MICs obtained for organisms in the
first group were significantly higher than those for organisms in
the second group; to wit, it appears that the BLNAR strains
identified in this study truly do represent a distinct subpopu-
lation ofH. influenzae isolates. Alterations in penicillin-binding
proteins have been proposed as a mechanism of resistance in
BLNAR isolates of H. influenzae (5, 16, 19, 22). Our observa-
tions concerning the phenotypic expression of resistance are
consistent with such a mechanism.
A second striking observation in this study was the recovery
of 17 strains of non-type b b-lactamase-producingH. influenzae
which appeared to be resistant to the combination A-C. Ex-
tensive secondary testing confirmed our initial findings with
these strains. We have coined the acronym BLPACR as a
designation for these strains. Two isolates of non-type b H.
influenzae with a comparable phenotype have previously been
recovered from human specimens in San Antonio, Tex. (11a).
However, we are not aware of any published descriptions of
such strains.
Potential explanations for this phenotype include hyperpro-
duction of a TEM-1 or ROB-1 b-lactamase, production of an
altered TEM-1 or ROB-1 b-lactamase that has become resis-
tant to clavulanate inhibition, production of a completely novel
b-lactamase that is not effectively inhibited by clavulanate, or
elaboration of altered penicillin-binding proteins superim-
posed on typical TEM-1 or ROB-1 b-lactamase production.
Efforts to delineate the precise mechanism of resistance in
these strains have been undertaken.
Our observations regarding the emergence of BLNAR and
BLPACR strains of H. influenzae, if corroborated, have nu-
merous ramifications. With the exception of cefixime and cef-
podoxime, the in vitro activities of all of the b-lactams exam-
ined in this study, including the b-lactamase inhibitor
combination A-C, were significantly diminished against these
isolates. This may be of clinical significance. Furthermore, if
BLNAR and BLPACR strains of H. influenzae become com-
mon, laboratory strategies for in vitro susceptibility testing may
have to change. Specifically, isolates of H. influenzae found to
be b-lactamase negative could not be considered a priori to be
susceptible to ampicillin, A-C, and the six oral cephalosporins
examined in this study. Rather, susceptibility tests which di-
rectly assess the activities of these agents would be needed.
Similarly, it would be inappropriate to consider b-lactamase-
positive strains to be uniformly susceptible to A-C. Again, a
direct test of A-C activity would be necessary.
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